XWELL (XWEL)
NASDAQ:XWEL
Top Page
XWELL
(NASDAQ:XWEL)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.30
▼(-40.20% Downside)
Action:ReiteratedDate:01/31/26
The score is driven primarily by weak financial performance (losses, negative equity, and continued cash burn). Technicals add further pressure with a clear downtrend, while valuation is hard to support given negative earnings and no dividend. A Nasdaq delisting notice adds incremental downside risk.
Positive Factors
Diversified revenue streams
XWELL sells services across kiosks, screenings and telehealth and partners with airports and corporates. Multiple service lines and B2B contracts provide durable revenue diversification and recurring-fee opportunities that improve resilience versus a single-product model.
Negative Factors
Negative shareholders' equity
Cumulative losses driving negative equity materially weaken the balance sheet, reduce financial shock absorption, constrain borrowing capacity and limit strategic options. This structural impairment raises long-term refinancing and covenant risks for the business.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified revenue streams
XWELL sells services across kiosks, screenings and telehealth and partners with airports and corporates. Multiple service lines and B2B contracts provide durable revenue diversification and recurring-fee opportunities that improve resilience versus a single-product model.
Read all positive factors
XWELL (XWEL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.92M
Dividend YieldN/A
Average Volume (3M)79.79K
Price to Earnings (P/E)―
Beta (1Y)0.32
Revenue Growth-12.74%
EPS Growth13.22%
CountryUS
Employees246
SectorHealthcare
Sector Strength45
IndustryPersonal Products & Services
Share Statistics
EPS (TTM)-0.26
Shares Outstanding5,766,703
10 Day Avg. Volume196,854
30 Day Avg. Volume79,787
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-8.84
Price to Sales (P/S)0.21
P/FCF Ratio-0.54
Enterprise Value/Market Cap1.85
Enterprise Value/Revenue0.43
Enterprise Value/Gross Profit2.34
Enterprise Value/Ebitda-1.37
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
XWELL Business Overview & Revenue Model
Company Description
XWELL Inc., a health and wellness services company, provides spa services at airports. It operates through XpresSpa, XpresTest, Treat, and HyperPointe brands. The company offers spa services, including massage, and nail and skin care, as well as s...
How the Company Makes Money
XWELL generates revenue through multiple streams, primarily by offering wellness services and health screenings at strategic locations such as airports and corporate offices. The company charges fees for its health services and product offerings, ...
XWELL Earnings Call Summary
Earnings Call Date:Nov 14, 2024
(Q3-2024)
| % Change Since: |
Next Earnings Date:Apr 21, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in revenue growth, strategic market expansion, and cost reductions, with improved financial metrics compared to the previous year. However, there were challenges such as increased salaries and legal expenses. Overall, the positive aspects and strategic advancements outweigh the negatives.Positive Updates
Revenue Growth
Total revenue for Q3 2024 was approximately $8.4 million, up from $7.5 million in the prior year period.
Negative Updates
Increased Salaries and Benefits
Salaries and benefits were approximately $1.9 million in Q3 2024, compared to $1.2 million in the same period in 2023.
Read all updates
Q3-2024 Updates
Positive
Negative
Revenue Growth
Total revenue for Q3 2024 was approximately $8.4 million, up from $7.5 million in the prior year period.
Read all positive updates
Company Guidance
During the XWELL Q3 2024 earnings call, several key metrics and strategic initiatives were highlighted. Total revenue for the quarter was approximately $8.4 million, a notable increase from $7.5 million in the same period last year. Revenue sources included $4.9 million from XpresSpa and Treat locations, $3.1 million from XpresTest, and $0.4 million from Naples Wax Center. Operating expenses significantly decreased to $6.8 million from $13.2 million in Q3 2023, contributing to a reduced operating loss of $4.8 million compared to $12.1 million the previous year. The company has also made strides in cost management, with a 35% reduction in total operating expenses over the first nine months of 2024 compared to the same period in 2023. XWELL is focusing on expanding its market presence, particularly in Florida, and is set to open new locations, including its first Naples Wax location and a spa at Penn Station. The company maintains a solid liquidity position with $4.4 million in cash and $11.7 million in marketable securities, with no long-term debt.XWELL Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Dec 2021 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 29.52M | 33.90M | 30.11M | 55.94M | 73.73M | 8.38M |
| Gross Profit | 5.49M | 8.92M | 3.68M | 12.05M | 32.34M | -3.60M |
| EBITDA | -9.38M | -11.16M | -15.75M | -19.12M | 8.14M | -17.52M |
| Net Income | -15.31M | -16.85M | -27.74M | -32.84M | 3.35M | -90.49M |
Balance Sheet | ||||||
| Total Assets | 21.74M | 25.35M | 38.99M | 70.43M | 127.27M | 103.13M |
| Cash, Cash Equivalents and Short-Term Investments | 4.22M | 11.80M | 23.05M | 42.19M | 105.51M | 89.80M |
| Total Debt | 9.89M | 10.77M | 11.09M | 14.11M | 13.82M | 15.38M |
| Total Liabilities | 18.68M | 17.61M | 18.02M | 22.48M | 27.33M | 22.76M |
| Stockholders Equity | -6.33M | -788.00K | 13.00M | 39.93M | 92.73M | 77.81M |
Cash Flow | ||||||
| Free Cash Flow | -15.12M | -12.80M | -18.45M | -31.02M | 6.97M | -29.36M |
| Operating Cash Flow | -12.13M | -11.01M | -16.07M | -24.19M | 14.56M | -25.01M |
| Investing Cash Flow | 8.51M | 5.89M | 5.65M | -34.84M | -5.16M | -4.35M |
| Financing Cash Flow | 2.78M | 1.36M | 8.00K | -27.38M | 6.35M | 117.22M |
XWELL Technical Analysis
Positive
0.50
Price Trends
0.83
Positive
0.77
Positive
0.91
Positive
Market Momentum
0.11
Positive
51.07
Neutral
15.31
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XWEL, the sentiment is Positive. The current price of 0.5 is below the 20-day moving average (MA) of 1.38, below the 50-day MA of 0.83, and below the 200-day MA of 0.91, indicating a neutral trend. The MACD of 0.11 indicates Positive momentum. The RSI at 51.07 is Neutral, neither overbought nor oversold. The STOCH value of 15.31 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XWEL.
XWELL Risk Analysis
XWELL disclosed 52 risk factors in its most recent earnings report. XWELL reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
XWELL Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $8.69M | -0.60 | 48.22% | ― | 13.71% | ― | |
52 Neutral | $59.60M | 37.76 | 71.09% | ― | 13.98% | 34.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $107.16M | -1.62 | -8.89% | ― | -36.29% | -96.65% | |
40 Underperform | $6.92M | -1.97 | 357.74% | ― | -12.74% | 13.22% | |
| ― | $8.05M | -0.82 | -1.53% | ― | -2.53% | 99.45% | |
41 Neutral | $2.52M | -0.27 | -144.87% | ― | 207.23% | 99.88% |
* Healthcare Sector Average
XWEL
XWELL
1.20
0.18
17.65%
MED
Medifast
9.75
-3.73
-27.67%
RGS
Regis
23.85
5.70
31.40%
MRM
MEDIROM Healthcare Technologies
1.10
0.73
197.30%
EJH
E-Home Household Service Holdings
0.10
-58.40
-99.83%
TRNR
Interactive Strength Inc
1.24
-121.76
-98.99%
XWELL Corporate Events
Business Operations and StrategyRegulatory Filings and ComplianceShareholder MeetingsStock Split
XWELL Shareholders Approve Reverse Split, Capital Flexibility Moves
Neutral
Dec 18, 2025
On December 18, 2025, XWELL, Inc. held its 2025 Annual Meeting of Stockholders, where holders of approximately 66.9% of outstanding common shares were represented in person or by proxy. Stockholders re-elected five directors to serve until the 202...
Delistings and Listing ChangesRegulatory Filings and Compliance
XWELL Faces Nasdaq Delisting Notice Over Bid Price
Negative
Dec 5, 2025
On December 1, 2025, XWELL, Inc. received a notification from Nasdaq indicating that the company did not meet the minimum bid price requirement of $1.00 per share for its common stock over a 30-day period. XWELL has been given a compliance period ...
Private Placements and FinancingRegulatory Filings and Compliance
XWELL Finalizes Securities Exchange Agreement with Amendments
Neutral
Nov 14, 2025
XWELL, Inc. entered into a Securities Exchange and Amendment Agreement with holders of its Series G Convertible Preferred Stock on November 3, 2025. The agreement involved exchanging a portion of the company’s outstanding Series G Preferred ...
Shareholder Meetings
XWELL Announces 2025 Annual Meeting Date Change
Neutral
Nov 7, 2025
On November 6, 2025, XWELL, Inc. announced that its 2025 Annual Meeting of Stockholders will be held on December 18, 2025. The company has changed the meeting date by more than 30 days from the previous year, prompting a new deadline for stockhold...
Private Placements and Financing
XWELL Agrees to Exchange Series G Stock for Notes
Neutral
Nov 4, 2025
XWELL, Inc. entered into a Securities Purchase Agreement on January 14, 2025, with accredited investors to sell Series G Convertible Preferred Stock and warrants. On November 3, 2025, the company agreed to exchange a portion of this stock for seni...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.